scholarly journals High Pregnane X Receptor (PXR) Expression Is Correlated with Poor Prognosis in Invasive Breast Carcinoma

Diagnostics ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1946
Author(s):  
Stamatios Theocharis ◽  
Constantinos Giaginis ◽  
Stefania Gourzi ◽  
Paraskevi Alexandrou ◽  
Gerasimos Tsourouflis ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Tumor Cells ◽  
Cell Lines ◽  
Histological Grade ◽  
Pregnane X Receptor ◽  
Invasive Breast Carcinoma ◽  
Clinicopathological Parameters ◽  
Hormonal Status ◽  
Proliferative Capacity ◽  
Cox Regression Analysis

Pregnane X Receptor (PXR) is involved in human cancer, either by directly affecting carcinogenesis or by inducing drug-drug interactions and chemotherapy resistance. The clinical significance of PXR expression in invasive breast carcinoma was evaluated in the present study. PXR protein expression was assessed immunohistochemically on formalin fixed paraffin-embedded breast invasive carcinoma tissue sections, obtained from 148 patients, and was correlated with clinicopathological parameters, molecular phenotypes, tumor cells’ proliferative capacity, and overall disease-free patients’ survival. Additionally, the expression of PXR was examined on human breast carcinoma cell lines of different histological grade, hormonal status, and metastatic potential. PXR positivity was noted in 79 (53.4%) and high PXR expression in 48 (32.4%), out of 148 breast carcinoma cases. High PXR expression was positively associated with nuclear grade (p = 0.0112) and histological grade of differentiation (p = 0.0305), as well as with tumor cells’ proliferative capacity (p = 0.0051), and negatively with luminal A subtype (p = 0.0295). Associations between high PXR expression, estrogen, and progesterone receptor negative status were also recorded (p = 0.0314 and p = 0.0208, respectively). High PXR expression was associated with shorter overall patients’ survival times (log-rank test, p = 0.0009). In multivariate analysis, high PXR expression was identified as an independent prognostic factor of overall patients’ survival (Cox-regression analysis, p = 0.0082). PXR expression alterations were also noted in breast cancer cell lines of different hormonal status. The present data supported evidence that PXR was related to a more aggressive invasive breast carcinoma phenotype, being a strong and independent poor prognosticator.

scholarly journals Immunohistochemical expression of cyclin D1 in invasive breast carcinoma and its correlation with clinicopathological parameters

2020 ◽  
Vol 63 (3) ◽  
pp. 376
Author(s):  
SiddhiGaurish Sinai Khandeparkar ◽  
PranotiVitthalrao Lengare ◽  
AvinashR Joshi ◽  
BageshriP Gogate ◽  
SmitaGaneshrao Solanke ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Cyclin D1 ◽  
Invasive Breast Carcinoma ◽  
Clinicopathological Parameters ◽  
Immunohistochemical Expression

CLINICAL AND HISTOPATHOLOGICAL REVIEW OF INVASIVE BREAST CARCINOMA IN A TERITARY CARE CENTRE.

2021 ◽  
pp. 18-21
Author(s):  
A. Gomathy ◽  
Muruganantham Arunagirinathan ◽  
I. Nithya
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Cancer Survival ◽  
Histological Grade ◽  
Lymph Node Involvement ◽  
Left Breast ◽  
Invasive Breast Carcinoma ◽  
Indian Women ◽  
Node Involvement ◽  
Grade Ii

BACKGROUND: Breast cancer accounts for 14% of all cancers in Indian women, that can occur at any age. Cancer survival becomes more difcult in higher stages of tumour, hence in order to improve the survival of affected persons, early diagnosis of breast cancer is critical. METHODS: Retrospective study of 48 mastectomy specimens with relevant clinical details and respective H&E stained slides were reviewed. CONCLUSION: This review showed that occurrence of Invasive Breast Carcinoma(IBC) peaks in the age group of 41-50years (35.4% ) with right and left breast being affected equally in the ratio of R:L – 1 : 1. Most of the IBC (91.6%) were of No Special Type (NST), with 75% of tumours were of Histological Grade II. 58.3% of tumours were of tumour stage T along with lymph node involvement in equal number of cases.

Clinicopathological significance of WT1 expression in invasive breast carcinoma with >90% mucinous component

2021 ◽  
pp. jclinpath-2021-207464
Author(s):  
Xiaoli Xu ◽  
Rui Bi ◽  
Ruohong Shui ◽  
Baohua Yu ◽  
Yufan Cheng ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Growth Pattern ◽  
Histological Grade ◽  
Invasive Breast Carcinoma ◽  
Nuclear Grade ◽  
Proliferation Index ◽  
Her2 Overexpression ◽  
Ki 67 ◽  
Mucinous Component ◽  
Clinicopathological Significance

AimsThis study was aimed to investigate the clinicopathological significance of immunohistochemical (IHC) Wilm’s tumour 1 (WT1) expression in invasive breast carcinoma with >90% mucinous components.MethodsOne hundred specimens of invasive breast carcinoma with >90% mucinous component were collected. All H&E-stained slides were reviewed, and the clinicopathological data, including sex, age, tumour size, nuclear grade, histological grade, growth pattern and lymph node (LN) status, were collected. IHC staining of WT1, oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 was performed. Fluorescence in situ hybridisation was used to verify the amplification of the HER2 gene. The relationship between WT1 expression and clinicopathological features was analysed statistically.ResultsWT1 expression was detected in 67% (67/100) of invasive breast carcinoma with >90% mucinous components. WT1 expression was significantly associated with low-to-intermediate nuclear grade/histological grade, ER and PR positivity, HER2 negativity, Ki-67 proliferation index <30% and noLN metastasis (all p<0.001). Micropapillary architecture was observed in 80% of cases. WT1 expression was not significantly correlated with different percentage of micropapillary components (p=0.422). None of the histological grade 3 tumours, tumours with HER2 overexpression/amplification and triple-negative specimens showed WT1 expression.ConclusionsWT1 expression was significantly related with low-intermediate nuclear/histological grade, ER positivity, HER2 negativity, a lower Ki-67 proliferation index and no LN metastasis in invasive breast carcinoma with >90% mucinous component. The micropapillary growth pattern in this type of tumour did not show a specific relationship with WT1 expression.

Isolated Tumor Cells in Sentinel Lymph Nodes of Primary Invasive Breast Carcinoma: A Cohort Analysis

2019 ◽  
Vol 19 (4) ◽  
pp. 286-291
Author(s):  
Gillian C. Bethune ◽  
Manolhas A. Karkada ◽  
Ryan DeCoste ◽  
Penny J. Barnes ◽  
Daniel Rayson
Keyword(s):  
Breast Carcinoma ◽  
Lymph Nodes ◽  
Tumor Cells ◽  
Cohort Analysis ◽  
Sentinel Lymph Nodes ◽  
Invasive Breast Carcinoma ◽  
Isolated Tumor Cells

scholarly journals Endogenous IL-2 in Cancer Cells: A Marker of Cellular Proliferation

1998 ◽  
Vol 46 (5) ◽  
pp. 603-611 ◽  
Author(s):  
Torsten E. Reichert ◽  
Simon Watkins ◽  
Joanna Stanson ◽  
Jonas T. Johnson ◽  
Theresa L. Whiteside
Keyword(s):  
Cell Cycle ◽  
Tumor Cells ◽  
Cell Lines ◽  
Cellular Proliferation ◽  
Histological Grade ◽  
Interleukin 2 ◽  
Ki 67 ◽  
Human Carcinoma

We have previously demonstrated that interleukin-2 (IL-2) receptors, IL-2 protein, and mRNA for IL-2 are present in human carcinomas in vitro and in vivo. Carcinoma cells synchronized in the G2/M-phase of the cell cycle express significantly more intracytoplasmic IL-2 as well as IL-2R-β and -γ than tumor cells in the G0/G1-phase. Here we evaluated immunohistologically the cell cycle-dependent distribution of the proliferation-associated Ki-67 antigen and expression of the cytokine IL-2 in four different carcinoma cell lines. In addition, 34 tissue samples from patients with squamous cell carcinomas of the head and neck were simultaneously analyzed for Ki-67 and IL-2 expression and the data were correlated to the histological grade of the tumors. All tumor cell lines were shown to express IL-2 in the Golgi complex. The strongest IL-2 expression was seen in tumor cells undergoing mitosis, identified by double staining with the antibody to Ki-67. In the tumor tissue, the highest level of co-expression of IL-2 and Ki-67 was observed in poorly differentiated carcinomas, with a labeling index (LI) of 67.2% for IL-2 and 68.8% for Ki-67. Well-differentiated carcinomas showed a significantly lower expression of both proteins (LI 35.0% for IL-2 and 26.5% for Ki-67). The correlation between the labeling indices was statistically significant ( r = 0.747; p<0.001). These results demonstrate that IL-2 expression in human carcinoma tissues is strongly associated with cell proliferation and significantly correlates with the histological tumor grade.

scholarly journals Expression of Survivin in Basal-Like and Triple Negative Breast Carcinoma and Associations with Clinicopathological Parameters

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Madatang A. ◽  
Mohd Nafi S.N. ◽  
Jaafar H. ◽  
Wan Abdul Rahman W.F.
Keyword(s):  
Breast Carcinoma ◽  
Triple Negative ◽  
Molecular Subtype ◽  
Survivin Expression ◽  
Prognostic Indicator ◽  
Invasive Breast Carcinoma ◽  
Clinicopathological Parameters ◽  
Tubule Formation ◽  
Cross Sectional ◽  
Triple Negative Breast Carcinoma

INTRODUCTION: Triple negative breast carcinoma (TNBC) molecular subtype and its variant; basal-like triple negative (BLTN) carcinoma is an established poor prognostic indicator. The aim of this study is to analyse the survivin expression in TNBC and BLTN, and relating the results with clinicopathological parameters. MATERIALS AND METHODS: We conducted a cross sectional study using 94 archived formalin-fixed paraffin embedded tissue blocks of invasive breast carcinoma, no special type (NST). Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (HER2) were used as surrogate markers to classify the cases into molecular subtypes. Samples with triple negative phenotype (ER, PR and HER2 negative) were stained with CK 5/6 to identify the BLTN subtype. All the samples were also immunostained for survivin. RESULT: Out of 94 cases, 41.5% (39 cases) were TNBC. Among the TNBC cases, only 41.0% (16 cases) were BLTN subtype when they found to be positive for CK 5/6. Among 94 cases of invasive breast carcinoma, 28.7% (27 cases) were survivin positive with (53.8%) 21 cases were TNBC and (11%) 6 cases were non-TNBC (p< 0.001). Among 16 cases of BLTN subtype, only 8 cases were survivin positive (p = 0.752). Survivin expression was also statistically significant with tubule formation (p=0.029), nuclear pleomorphism (p=0.008), tumour grade (p=0.010), ER status (p< 0.001) and PR status (p=0.001). CONCLUSION: Survivin expression was statistically significant in invasive breast carcinoma. Even though the expression was significantly high in TNBC, it is not related to whether it is a basal-like or non-basal-like variant.

scholarly journals The Construction and Analysis of a Novel Four-Long Non-Coding RNA Signature Predicting Survival of Breast Cancer Patients

2021 ◽  
Author(s):  
Chengdong Qin ◽  
Weiliang Feng ◽  
Xingfei Yu ◽  
Chenlu Liang ◽  
Yuqin Ding ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Cox Regression ◽  
Expression Profiles ◽  
Functional Enrichment ◽  
Risk Scores ◽  
Clinicopathological Parameters ◽  
Differential Analysis ◽  
Breast Cancer Patients ◽  
Cox Regression Analysis

Abstract Background As the critical regulators for tumorigenesis and progression, long-noncoding RNAs (lncRNAs) are becoming novel prognostic biomarkers for tumor patients. By the levels of lncRNAs expression, the patients with breast carcinoma may be divided into subgroups with different risk scores. Nevertheless, there is limited evidence to evaluate the role of lncRNAs in the prognosis of breast carcinoma. The present study aimed to construct lncRNA signatures for prognostic analysis and assist clinicians in choosing optimal therapies. Methods Abnormal expression profiles of breast cancer-associated lncRNAs were analyzed based on the TCGA datasets. Univariate and multivariate Cox regression analysis was used to build a prognostic risk signature according to the lncRNAs expression. The prognostic ability of this signature was verified in various subgroups. Functional enrichment analysis was employed to reveal the potential roles of these predictive lncRNAs in cancer-related biological processes and pathways. Results Compared with normal breast tissues, the differential analysis demonstrated that 286 lncRNAs were abnormally expressed in breast carcinoma. A four-lncRNA signature (RP1-193H18.2, AL022341.3, WDR86-AS1, LINC00511) was found to be closely related to the prognosis of breast carcinoma. The four-lncRNA signature could also qualify the magnitude of treatment benefits for different breast cancer subtypes. Additionally, it was an independent risk factor out of other clinicopathological parameters based on the multivariate Cox analysis. We also uncovered that the four predictive lncRNAs are involved in multiple cellular progression and pathways of breast cancer. Conclusions The four-lncRNA signature could be an essential reference for prognostic prediction and making therapeutic strategies.

Sign in / Sign up

Export Citation Format

Share Document